A number of activities in the complement system are known to be associated with cells of the immune system. In common with many other tissue cells such as macrophages, polymorphs and platelets, lymphocytes and lymphoblastoid cells of the B cell lineage have membrane receptors for C3b (Henson 1972 , Nussenzweig 1975 . C3d receptors on lymphocytes, however, are apparently not identical to the C3b receptors on nonlymphoid cells (Ross et al. 1973) . C3 also appears to be involved in the induction of the allergic response to thymus-dependent antigens (Pepys 1972) and probably also in the localization of antigen-antibody complexes within germinal centres (Papamichail et al. 1975 , White et al. 1975 ). C8, one of the terminal lytic components, has also been shown to be associated with certain types of cytotoxic lymphocytes (Perlmann et al. 1974) . More recently, two other types of complementlike activities have been recognized as being associated with lymphoid cells (Halbwachs et al. 1975 , Halbwachs & Lachmann 1976 ). Both of these activities are associated with the alternative pathway of complement activation and are described below.
Complement Activation Classical pathway: Activation of C3 is one of the central events of the complement sequence and is probably biologically the most significant part of the sequence. There are two immunological C3 converting enzymes (C3 convertases) which are the end-products of the classical and the alternative pathways of complement activation (Lach-Ag/Ab complexes (Fig 1) is initiated by antigenantibody complexes and involves the early number components, Cl, C4, C2 leading to the generation of an active enzyme a2 which splits C3 to C3b. The alternative pathway of complement activation involves the components of the properdin system (Pillemer et al. 1954 ). These are properdin, factor D and factor B. Although there are a large number of substances which can activate the alternative pathway, such as yeast cell wall polysaccharides (zymosan), Gramnegative bacteria, endotoxin and a factor from cobra venom, as well as immunoglobulin aggregates, the exact initiating mechanisms are unknown. Alternative pathway activation may be conveniently distinguished from the classical pathway in a variety of ways; it takes place in concentrated and not dilute sera, can occur in sera genetically deficient in C4 or C2 and requires Mg++ but not Ca++.
Alternative pathway: The C3 convertase generated by alternative pathway activation is a complex of C3b and factor B (C3b,Bb). Since C3b, a product of classical pathway activation, can itself promote C3 splitting via the C3b feedback cycle, there must clearly be a mechanism for inactivating C3b else the splitting of a single C3 would lead to massive complement activation. This is achieved by the action of the C3b inactivator (KAF), an enzyme which destroys much of the biological activity of C3, especially its ability to fire the feedback cycle and to take part in adherence reactions with non-lymphoid cells. KAF-reacted C3b can bind to some lymphocytes.
There is a factor in cobra venom (CVF), which can also split C3 but which spares Cl, C4 and C2. This also acts via the alternative pathway in a manner analogous to C3b. It has recently been shown that the factor involved seems to be cobra C3b (Alper & Balavitch 1976 ). Because CVF is not susceptible to the activities of mammalian KAF it -is a profound activator of the alternative pathway causing extensive splitting of C3. The formation of a CVF,Bb, convertase is apparently a specific test for factor B-like activity. This reaction sequence features largely in the system described here.
Assaysfor Factor B on Lymphocytes
The assays for factor B activity on lymphocytes rely on the ability of these cells to replace factor B in the generation of an alternative pathway convertase with CVF. Lymphocytes are incubated with CVF and factor D for five minutes at 370C. The cells are then centrifuged and the supernatant assayed for the C3 convertase (CVF,B1). The splitting of C3 is measured -by two-dimensional crossed-electrophoresis (Laurell 1965) .' In mice it has also been possible to detect factor B-like activity at the single cell level. This assay relies on the fact that a membrane-associated convertase, CVF,Bb, is generated on or near the surface of factor B-positive lymphocytes after incubation with CVF and serum depleted in factor B. C3 conversion in the vicinity of the convertase results in C3 deposition on the lymphocyte surface which can then be detected by immunofluorescence.
Factor B on human lymphocytes: Several human cell types have been shown to have factor B activity. Table 1 , which summarizes data from Halbwachs & Lachmann (1976) , shows that normal peripheral blood lymphocytes, lymphocytes from patients with chronic lymphocytic -leukemia, lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and cultured for several months in vitro, all have factor B activity. Thymus cells and erythrocytes are negative. The membrane-associated CVF,Bb convertase does not remain associated with cells after their incubation with CVF. After five minutes' incubation of Raji cells with CVF and purified factor D, substantial C3 convertase activity can be detected in the supernatant. If Raji cells are disrupted by repeated freezing and thawing no convertase activity can be detected, indicating that the activity is not due to release of some intracellular enzyme from the cells. Furthermore, addition of F(abl), anti-factor B to the mixture of CVF and cells will inhibit the production of a CVF,Bb convertase showing that cell associated factor B is antigenically identical to serum factor B. The generation of the convertase occurs via the alternative pathway since it is Mg++ but not Trypsin treatment of cells prior to incubation with CVF, although destroying the C3b receptors, has no effect on the ability of the CVF to induce convertase formation. The exact mechanism whereby CVF induces the release from, or the synthesis of factor B and the convertase from, cells is unknown. It may be thatabriefencounterof CVF with some membrane component is sufficient to induce or promote the release of factor B associated with CVF.
Factor B-like activity associated with mouse lymphocytes: Mouse lymphocytes similarly have factor B-like activity. As shown in Table 2 considerable C3 conversion is observed when mouse lymph node cells are incubated with CVF in mouse serum heated to destroy factor B (HMS). The convertase is generated after incubation at 37°C for five minutes. After this time the activity does not appear to remain associated with the lymphocyte surface and is only detectable in the supernatant serum. Using the single cell assay for factor B, 24 % of mouse lymph node cells were shown to be fluorescent for C3 (Table 3) . These cells are believed to be positive for factor B-like activity. Only 6% of cells are C3 positive when incubated with HMS alone, CVF alone or when HMS-EDTA is used instead of HMS. This latter reagent does not support complement activation. About 25% of cells are C3 positive when incubated with CVF and HMS-EGTA+Mg++, a reagent which supports alternative but not classical pathway activation. The activity seems to be mainly associated with the B lymphocyte population (Table 4 ) since removal of B lymphocytes from lymph node cell suspensions, using the technique of Fc rosette depletion, greatly reduces both immunoglobulin-positive and factor B-positive cells. Thymus cells were also negative in this assay. In the absence of a specific antibody to mouse factor B, it cannot be concluded that the activity is identical to serum factor B. Thus it is described only as being factor B-like.
Different strains of mice have been shown to have different levels of cells with factor B-like activity (Table 4 ). Balb/c mice (H-2d haplotype) have a significantly greater percentage of reactive lymphocytes (mean 24.8 %) than CBA strain mice (H-2k haplotype) (mean 11.1 %). This difference is not due to the differences in the level of B lymphocytes in these mice since they have similar numbers of C3 receptor-bearing cells. Preliminary breeding experiments have indicated that this difference in level may be linked to the H-2 complex.
In summary, an activity resembling factor B of the alternative pathway of complement activation can be detected on lymphocytes by a functional assay involving incubation of the cells with cobra venom factor. In the human this has been shown to be specifically inhibited by an antiserum to factor B and from this it has been concluded that lymphocytes either have on their surface or secrete factor B. Although thymus cells and erythrocytes are negative it is difficult to exclude the possibility that the factor B has not been absorbed from the sera. The detection of factor B on Raji cells, a continuous line of human B lymphocytes grown in fetal calf serum devoid of factor B, shows that in this case exogenous factor B is not involved. Alternative Pathway Activation by Cell Surfaces in the Absence ofAntibody The alternative pathway can be activated by a number of substances which are not immunoglobulin and which show no obvious requirement for a conventional antibody. Zymosan, inulin, bacterial lipopolysaccharides, CVF, even magnesium ions all trigger alternative pathway activation (Lachmann 1975) . The initiating microevent involved in this system is unknown, and once trace amounts of C3b have been generated activation can proceed via the C3b feedback cycle. Recent studies have shown that a variety of cell types can similarly activate the alternative pathway albeit in heterologous sera. Platts-Mills & Ishizaka (1974) have shown that rabbit red cells and thymocytes activate the alternative pathway in normal human serum. Trypanosomes also activate complement by the alternative pathway by an apparently non-antibody-mediated mechanism (Keirszenbaum et al. 1976 ). This activation when it occurs in normal chicken serum produces Jysis of the parasite and as such may represent an important in vivo mechanism for eliminating parasites.
Two studies have shown that cultured human tumour cell lines can activate the alternative pathway in autologous sera. Okada & Baba (1974) have shown that tumour cells derived from an oat cell carcinoma can activate the alternative pathway, have independently shown that cultured lymphoblastoid cells derived from patients with Burkitt's lymphoma and infectious mononucleosis can similarly activate the alternative pathways in autologous as well as heterologous sera. In the latter case this phenomenon was conveniently demonstrated using Raji cells which have membrane receptors for C3b, but other cell lines which lack C3b receptors also produce the same effect. Activation was measured either by measuring C3 conversion in the supernatant serum or by detecting C3 deposits on the surface of the activating cells. The latter can be detected either by immunofluorescence or by the blocking of the C3b receptor.
A variety of cell types have been tested for alternative pathway activation by Budzko et al. (1976) and some of these results are summarized in Table 5 . In vitro cultured cell lines derived from patients with Burkitt's lymphoma or infectious mononucleosis can activate the alternative pathway. Cells from patients with chronic lymphocytic leukiemia or macroglobulinamia do not. Complement activation occurs exclusively by the alternative pathway. C4 deficient and C2 deficient sera support activation as well as normal sera, and this activation is dependent on magnesium but not calcium ions. It also shows a strict requirement for factor B but little requirement-for factor D or properdin. In this respect this type ofactivation resembles that produced by C3 nephritic factor. The activation is independent of antibody, proceeds in hypogammaglobulinemic human serum and agammaglobulinemic chicken serum and cannot be removed by repeated absorption of normal human serum with Raji cells. A variety of different species sera will support activation but lysis is only observed with chicken sera. 
Discussion
The detection of complement-like activities on lymphoid cells indicates a possible relationship between the components of the complement system and the cells of the immune system. The complement system represents an important group of serum factors which are primarily involved as humoral effector mechanisms for the elimination of foreign antigen, and their association with the specific cells of the lymphoid system is a phenomenon deserving further study. Furthermore there is considerable evidence to show that certain complement components are genetically linked to the genes coding for the major histocompatibility antigens. In mice the Ss protein coded within the H-2 region is now known to be mouse C4 , and in guinea-pigs the 'C4 deficiency gene' is linked to the major histocompatibility system (MHS) (Shevach et al. 1976 ). In man, C2 deficiency (Fu et al. 1974 ) and factor B allotypes (Allen 1974) have been shown to be linked to the MHS. Together these various lines of evidence indicate that complement components and their activation may not be entirely restricted to the serum but possibly also occur at a cell membrane level as well. The significance of this remains to be understood.
